Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 133 to 135 of 135 entries
Sorted by: Best Match Show Resources per page
Effectiveness of a third dose of BNT162b2 mRNA vaccine.

The Journal of infectious diseases

Saciuk Y, Kertes J, Shamir Stein N, Ekka Zohar A.
PMID: 34726239
J Infect Dis. 2021 Nov 02; doi: 10.1093/infdis/jiab556. Epub 2021 Nov 02.

A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against covid-19 infection. Of nearly one million members receiving two doses of BNT162b2...

Cite
Saciuk Y, Kertes J, Shamir Stein N, et al. Effectiveness of a third dose of BNT162b2 mRNA vaccine. J Infect Dis. 2021;doi: 10.1093/infdis/jiab556.
Saciuk, Y., Kertes, J., Shamir Stein, N., & Ekka Zohar, A. (2021). Effectiveness of a third dose of BNT162b2 mRNA vaccine. The Journal of infectious diseases, . https://doi.org/10.1093/infdis/jiab556
Saciuk, Yaki, et al. "Effectiveness of a third dose of BNT162b2 mRNA vaccine." The Journal of infectious diseases vol. (2021). doi: https://doi.org/10.1093/infdis/jiab556
Saciuk Y, Kertes J, Shamir Stein N, Ekka Zohar A. Effectiveness of a third dose of BNT162b2 mRNA vaccine. J Infect Dis. 2021 Nov 02; doi: 10.1093/infdis/jiab556. Epub 2021 Nov 02. PMID: 34726239.
Copy Download .nbib Format: NLM
Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel.

Preventive medicine

Saciuk Y, Kertes J, Mandel M, Hemo B, Stein NS, Zohar AE.
PMID: 34974072
Prev Med. 2021 Dec 30;106947. doi: 10.1016/j.ypmed.2021.106947. Epub 2021 Dec 30.

Development of an effective vaccine against Covid-19 is crucial to reducing infection. mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first FDA-approved vaccinations reporting high efficacy (95%) and minimal side effects. Evaluating effectiveness of BNT162b2 in...

Cite
Saciuk Y, Kertes J, Mandel M, et al. Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Prev Med. 2021;106947doi: 10.1016/j.ypmed.2021.106947.
Saciuk, Y., Kertes, J., Mandel, M., Hemo, B., Stein, N. S., & Zohar, A. E. (2021). Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Preventive medicine, 106947. https://doi.org/10.1016/j.ypmed.2021.106947
Saciuk, Yaki, et al. "Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel." Preventive medicine vol. (2021): 106947. doi: https://doi.org/10.1016/j.ypmed.2021.106947
Saciuk Y, Kertes J, Mandel M, Hemo B, Stein NS, Zohar AE. Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Prev Med. 2021 Dec 30;106947. doi: 10.1016/j.ypmed.2021.106947. Epub 2021 Dec 30. PMID: 34974072.
Copy Download .nbib Format: NLM
Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel.

Preventive medicine

Saciuk Y, Kertes J, Mandel M, Hemo B, Shamir Stein N, Ekka Zohar A.
PMID: 34974072
Prev Med. 2021 Dec 30;155:106947. doi: 10.1016/j.ypmed.2021.106947. Epub 2021 Dec 30.

Development of an effective vaccine against Covid-19 is crucial to reducing infection. mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first FDA-approved vaccinations reporting high efficacy (95%) and minimal side effects. Evaluating effectiveness of BNT162b2 in...

Cite
Saciuk Y, Kertes J, Mandel M, et al. Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Prev Med. 2021;155:106947doi: 10.1016/j.ypmed.2021.106947.
Saciuk, Y., Kertes, J., Mandel, M., Hemo, B., Shamir Stein, N., & Ekka Zohar, A. (2021). Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Preventive medicine, 155106947. https://doi.org/10.1016/j.ypmed.2021.106947
Saciuk, Yaki, et al. "Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel." Preventive medicine vol. 155 (2021): 106947. doi: https://doi.org/10.1016/j.ypmed.2021.106947
Saciuk Y, Kertes J, Mandel M, Hemo B, Shamir Stein N, Ekka Zohar A. Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Prev Med. 2021 Dec 30;155:106947. doi: 10.1016/j.ypmed.2021.106947. Epub 2021 Dec 30. PMID: 34974072; PMCID: PMC8717697.
Copy Download .nbib Format: NLM
Showing 133 to 135 of 135 entries